Extract

Objectives

A new orodispersible film (ODF) formulation of Sildenafil has been developed for treatment of erectile dysfunction (ED),in order to overcome the drawbacks that some patients experience when taking the old conventional film-coated tablet (FCT).The aim is to assess the effectiveness and safety of Sildenafil ODF formulation in a group of patients with ED, who were using FCT.

Materials & Methods

Between May-July 2017, 139 patients with ED were enrolled. A penile color-duplex ultrasound, medical history, hormonal evaluation and patient self-administered questionnaires were collected. All patients were administered Sildenafil 100 mg FCT for 4 weeks. Thereafter, they underwent a 2-week wash-out period and subsequently took Sildenafil 75 mg ODF for 4 weeks.IIEF-15, Hospital Anxiety and Depression Scale (HADS), Patient Global Impressions of Improvement (PGI-I) and Clinician Global Impressions of Improvement (CGI-I) questionnaires were administered.

Results

Differences of IIEF-EF, IIEF-OF, IIEF-SD and IIEF-IS mean were significantly in favor of Sildenafil 100 mg FCT, while IIEF-OS was in favor of Sildenafil 75 mg ODF. (Figure1) Significant difference in HADS changes was found in the period between wash-out to final follow-up(mean difference:-0.19;p<0.01). According to the ODF formulation, median CGI-I was 3.5(IQR:2.5-4.5)and median PGI-I was 3.0(IQR:2-0-4.0). Median action time was 20.0 minutes (IQR:15.0-30.0) and the median mouth time 60.0(IQR:30.0-120.0).Table 1:baseline characteristics

You do not currently have access to this article.